CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Terminated
• CT.gov ID: NCT03002623
• Collaborator: (none)
• Enrollment: 7
• Location: 1
• Arm: 1
• Actual Duration (Months): 13.7
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

Background:

The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland. Researchers believe a new drug called CUDC-907 may be able to help people with thyroid cancer that has spread or has gotten worse.

Objective:

To see if CUDC-907 will shrink tumors in people with advanced thyroid cancer.

Eligibility:

People at least 18 years old who have been diagnosed with locally advanced and metastatic thyroid cancer.

Design:

Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Electrocardiogram (ECG) heart test.

Review of their symptoms and how they perform normal activities

A scan will be performed. Some will have a computed tomographic scan (CT) that takes pictures of the body using a small amount of radiation. Some will have magnetic resonance imaging (MRI) that uses a magnetic field to take pictures.

Bone scan (some participants)

Fludeoxyglucose (FDG) positron emission tomography (PET) scan to produce a tumor image.

A sample of their tumor from a previous surgery. They may have a biopsy of their tumor if a tumor sample is not available from a previous surgery.

Participants will be given CUDC-907 in tablet form. They will take it by mouth once a day for 5 days, then take 2 days off, each week.

While taking the study drug, participants will have study visits that repeat the screening tests.

After they stop treatment, participants will have 3 follow-up visits over a year. They will repeat some tests. Then participants will be contacted by phone or e-mail every 6 months....

Condition or Disease	Intervention/Treatment	Phase
Thyroid Neoplasms; Poorly Differentiated and Undifferentiated Thyroid Cancer; Differentiated Thyroid Cancer	Drug: CUDC-907	Phase 2

Detailed Description

Background:

• There are no standard or effective systemic therapies for metastatic or locally advanced poorly differentiated and undifferentiated thyroid cancer.

• Poorly differentiated and undifferentiated thyroid cancer are aggressive, with high mortality.

• CUDC-907 is a first-in-class dual inhibitor of histone deacetylase (HDAC) and PI3K signaling.

• Approximately 80% of poorly differentiated and undifferentiated thyroid cancers have driver mutations in the PI3K/AKT pathway or activation of the pathway.

• HDAC2 is upregulated in poorly differentiated and undifferentiated thyroid cancer, and aggressive variants of differentiated thyroid cancer, and CUDC-907 treatment reduces HDAC2 levels in thyroid cancer cells.

• CUDC-907 inhibits thyroid cancer cell growth, invasion and migration in vitro.

• In addition to inhibiting the PI3K/AKT signaling pathway, CUDC-907 inhibits the EGFR/RAS/RAF/MEK/ERK signaling pathway, which is also activated in poorly differentiated and undifferentiated thyroid cancer.

• CUDC-907 inhibits growth and metastases in a mouse model of metastatic thyroid cancer.

• We hypothesize that CUDC-907 will cause cancer regression in patients with metastatic and locally advanced poorly differentiated and undifferentiated thyroid cancer, and aggressive variants of differentiated thyroid cancer.

Objective:

-To determine response to CUDC-907 treatment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in patients with locally advanced and metastatic poorly differentiated and undifferentiated thyroid cancer, and aggressive variants of differentiated thyroid cancer.

Eligibility:

• Age greater than or equal to 18 years

• Thyroid cancer that is refractory to or relapsed after standard treatment.

• Aggressive thyroid cancer confirmed on histology or cytologic analysis.

• Measurable disease.

• Last dose of chemotherapy or last radiotherapy treatment more than 4 weeks prior to starting treatment with this protocol, except for subjects with anaplastic/undifferentiated thyroid cancer who may enroll immediately after discontinuation of previous therapy.

Design:

• Open label, phase II trial to determine response to CUDC-907 treatment.

• Patients will be given 60 mg of CUDC-907 orally for 5 consecutive days followed by 2 days off (5/2 schedule).

• One cycle is 21 days. Patients may continue on treatment if there is no disease progression.

• Initial anatomic and functional imaging will be performed at enrollment and after 2 cycles of treatment. Thereafter, anatomic imaging will be performed every two cycles of treatment.

Study Design

• Study Type: Interventional
• Actual Enrollment: 7 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: This is a single group assignment. All patients regardless of subtype of thyroid cancer received one single treatment and follow up plan with option to continue the treatment when scan was negative.This is a single group assignment. All patients regardless of subtype of thyroid cancer received one single treatment and follow up plan with option to continue the treatment when scan was negative.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer
• Actual Study Start Date: Dec 22, 2016
• Actual Primary Completion Date: Feb 12, 2018
• Actual Study Completion Date: Feb 12, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group CUDC-907 for thyroid cancer	Drug: CUDC-907; 60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.

Outcome Measures

Primary Outcome Measures

1. Number of Participants With a Clinical Response (Complete Response (CR) + Partial Response (PR)) Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [Approximately 6 months]

   Clinical response, defined as a complete response + partial response (CR+PR) to CUDC-907 treatment, was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response is at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

Secondary Outcome Measures

1. Median Amount of Time Subject Survives Without Disease Progression After Treatment [Approximately 6 months]

   Time in days from initiation of treatment until tumor grows more than 20%. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.

2. Median Amount of Time Subject Survives After Therapy [Approximately 12 months]

   Time in days from the initiation of treatment until death estimated by the Kaplan-Meier method.

3. Correlation Between Mutation Status of Tumor and Median Amount of Time Subject Survives Without Disease Progression After Treatment [At disease progression]

   The amount of time subject survives without disease progression is compared by patient tumor mutation status.

4. Correlation Between Activation of the Phosphoinositide 3-kinase (PI3K)/Protein Kinase B (AKT) and EGFR/RAS/RAF/MEK/ERK Pathways in Tumor Tissue and Median Amount of Time Subject Survives Without Disease Progression After Treatment [At disease progression]

   The amount of time subject survives without disease progression is compared by the protein levels of PI3K/AKT and epidermal growth factor receptor (EGFR)/rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/methyl ethyl ketone (MEK)/extracellular-signal regulated kinase (ERK) in tumor tissue.

5. Correlation Between Histone Deacetylase 2 (HDAC2) and Survivin Protein Levels in Tumor Tissue With Median Amount of Time Subject Survives Without Disease Progression After Treatment [At disease progression]

   The amount of time subject survives without disease progression is compared by the protein levels of HDAC2 and surviving in tumor tissue. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.

6. Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) [Date treatment consent signed to date off study, approximately 12 months and 13 days]

   Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 99 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

• INCLUSION CRITERIA:

• Subjects greater than or equal to 18 years of age.

• Thyroid cancer histology or cytology that is aggressive (anaplastic/undifferentiated thyroid cancer, poorly differentiated thyroid cancer, Hurthle cell carcinoma, tall-cell variant of papillary thyroid cancer, sclerosing variant of papillary thyroid cancer).

• Measurable disease.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Absolute neutrophil count greater than or equal to 1,000/microL

• Platelets greater than or equal to 75,000/microL

• Creatinine less than or equal to 1.5 times upper limit of normal (ULN) or creatinine clearance > 60ml for patients with creatinine levels 1.5 times above institutional ULN (calculated based on age, weight and sex

• Total bilirubin less than or equal to 1.5 times ULN; aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 times ULN. For subjects with documented liver metastases, the AST/ALT may be less than or equal to 5 times ULN.

• Recovery to Grade 1 or baseline of any toxicity due to prior anticancer therapies (excluding alopecia).

• Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days prior to screening complete blood count (CBC) or Cycle 1, Day 1 treatment.

• Women of child bearing potential must have a negative serum pregnancy test.

• The effects of CUDC-907 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 30 days following the last study treatment.

Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

-Able to provide written informed consent and to follow protocol requirements.

EXCLUSION CRITERIA:

• Systemic anticancer therapy within 4 weeks of study entry, except for subjects with anaplastic/undifferentiated thyroid cancer who may be enrolled immediately after discontinuation of previous therapy.

• Other investigational agents within 4 weeks prior to study treatment except for subjects with anaplastic/undifferentiated thyroid cancer who may be enrolled immediately of discontinuation of previous therapy.

• Pregnant women are excluded from this study because the potential risk of teratogenic or abortifacient effects of CUDC-907 is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CUDC-907, breastfeeding should be discontinued if the mother is treated with CUDC-907. These potential risks may also apply to other agents used in this study.

• Diabetes mellitus that is not controlled with medication.

• Serious infection requiring intravenous antibiotic therapy within 14 days prior to study treatment.

• Evidence of central nervous system metastasis.

• Uncontrolled or severe cardiovascular disease, including myocardial infarction, unstable angina, or atrial fibrillation (AFib) within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, cardiac amyloidosis, or corrected QT interval (QTc) with Fridericia's (QTcF) correction that is unmeasurable or greater than or equal to 480 msec on screening electrocardiogram (ECG). (Note: for QTcF greater than or equal to 480 sec on the screening ECG, the ECG may be repeated twice at least 24 hours apart; the mean QTcF from the three screening ECGs must be < 480 msec in order to meet eligibility for trial participation).

• Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of CUDC-907. This includes uncontrolled diarrhea (> 1 watery stool/day), major abdominal surgery, significant bowel obstruction and/or gastrointestinal diseases that could alter the assessment of pharmacokinetics or safety, including but not limited to: irritable bowel syndrome, ulcerative colitis, Crohn's disease and hemorrhagic coloproctitis.

• Unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a subject and/or compliance with the protocol.

• Second primary malignancy within 2 years of study entry other than adequately treated non-melanoma skin or superficial bladder cancer, curatively treated carcinoma in situ of the cervix or other curatively treated solid tumor deemed by the investigator to be at low risk for recurrence.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Institutes of Health Clinical Center	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Naris Nilubol, M.D., National Cancer Institute (NCI)

Study Documents (Full-Text)

• Study Protocol, Statistical Analysis Plan, and Informed Consent Form - Nov 13, 2017

More Information

Additional Information:

• NIH Clinical Center Detailed Web Page

Publications

• Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005 Apr 1;103(7):1330-5.
• Nilubol N, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer. 2015 Apr 1;121(7):1017-24. doi: 10.1002/cncr.29123. Epub 2014 Nov 25.
• Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998 Jun;22(6):569-74.

• Responsible Party: Naris Nilubol, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
• ClinicalTrials.gov Identifier: NCT03002623
• Other Study ID Numbers: 170029; 17-C-0029
• First Posted: Dec 26, 2016
• Last Update Posted: Dec 21, 2018
• Last Verified: Dec 1, 2018

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Naris Nilubol, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC): Dual Inhibitor of HDAC and P13K Signaling; HDAC2; EGFR/RAS/RAF/MEK/ERK Signaling Pathway Inhibition
• Additional relevant MeSH terms: Thyroid Neoplasms; Thyroid Carcinoma, Anaplastic; Thyroid Diseases

Study Results

Participant Flow

Arm/Group Title	Anaplastic Thyroid Cancer	Poorly Differentiated/Variants of Thyroid Cancer
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.	CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Period Title: Overall Study
STARTED	4	3
COMPLETED	2	2
NOT COMPLETED	2	1

Baseline Characteristics

Arm/Group Title	Anaplastic Thyroid Cancer	Poorly Differentiated/Variants of Thyroid Cancer	Total
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.	CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.	Total of all reporting groups
Overall Participants	4	3	7
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	2 50%	1 33.3%	3 42.9%
>=65 years	2 50%	2 66.7%	4 57.1%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	59.5 (19.18)	66.6 (1.39)	62.5 (16.15)
Sex: Female, Male (Count of Participants)
Female	2 50%	1 33.3%	3 42.9%
Male	2 50%	2 66.7%	4 57.1%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	0 0%
White	3 75%	3 100%	6 85.7%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	1 25%	0 0%	1 14.3%
Race/Ethnicity, Customized (Count of Participants)
Mexican, Puerto Rican, Cuban, Central/So American	0 0%	2 66.7%	2 28.6%
Not meeting definition for Hispanic or Latino	4 100%	1 33.3%	5 71.4%
Region of Enrollment (participants) [Number]
United States	4 100%	3 100%	7 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With a Clinical Response (Complete Response (CR) + Partial Response (PR)) Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Description	Clinical response, defined as a complete response + partial response (CR+PR) to CUDC-907 treatment, was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response is at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Time Frame	Approximately 6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Anaplastic Thyroid Cancer	Poorly Differentiated/Variants of Thyroid Cancer
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.	CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	4	3
Complete Response	0 0%	0 0%
Partial Response	0 0%	0 0%

2. Secondary Outcome

Title	Median Amount of Time Subject Survives Without Disease Progression After Treatment
Description	Time in days from initiation of treatment until tumor grows more than 20%. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
Time Frame	Approximately 6 months

Outcome Measure Data

Analysis Population Description

One participant was non-evaluable (withdrew consent).

Arm/Group Title	Anaplastic Thyroid Cancer	Poorly Differentiated/Variants of Thyroid Cancer
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.	CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	3	2
Median (Full Range) [Days]	31.3	147

3. Secondary Outcome

Title	Median Amount of Time Subject Survives After Therapy
Description	Time in days from the initiation of treatment until death estimated by the Kaplan-Meier method.
Time Frame	Approximately 12 months

Outcome Measure Data

Analysis Population Description

Participants are grouped together because of a small sample size and not enough power to compare the difference between two groups. No statistical analysis to be done.

Arm/Group Title	All Participants
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off. CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	6
Median (95% Confidence Interval) [Days]	127

4. Secondary Outcome

Title	Correlation Between Mutation Status of Tumor and Median Amount of Time Subject Survives Without Disease Progression After Treatment
Description	The amount of time subject survives without disease progression is compared by patient tumor mutation status.
Time Frame	At disease progression

Outcome Measure Data

Analysis Population Description

This outcome measure was not done. Data was collected but the correlation between mutation status of tumor and progression-free survival was not performed because of only BRAF V600E and the loss of tumor protein 53 (TP53) heterozygosity were found on a single patient each. Since only 1 mutant was found for each, no analysis was done.

Arm/Group Title	All Participants
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off. CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	0

5. Secondary Outcome

Title	Correlation Between Activation of the Phosphoinositide 3-kinase (PI3K)/Protein Kinase B (AKT) and EGFR/RAS/RAF/MEK/ERK Pathways in Tumor Tissue and Median Amount of Time Subject Survives Without Disease Progression After Treatment
Description	The amount of time subject survives without disease progression is compared by the protein levels of PI3K/AKT and epidermal growth factor receptor (EGFR)/rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/methyl ethyl ketone (MEK)/extracellular-signal regulated kinase (ERK) in tumor tissue.
Time Frame	At disease progression

Outcome Measure Data

Analysis Population Description

This outcome measure was not done. Data was collected but no samples were analyzed because the experiment was not technically successful due to inconclusive results from immunohistochemistry (study of protein levels in tumor tissue) analysis of P13K/AKT and EGFR/RAS/RAF/MEK/ERK proteins.

Arm/Group Title	All Participants
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off. CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	0

6. Secondary Outcome

Title	Correlation Between Histone Deacetylase 2 (HDAC2) and Survivin Protein Levels in Tumor Tissue With Median Amount of Time Subject Survives Without Disease Progression After Treatment
Description	The amount of time subject survives without disease progression is compared by the protein levels of HDAC2 and surviving in tumor tissue. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
Time Frame	At disease progression

Outcome Measure Data

Analysis Population Description

This outcome measure was not done. Data was collected but not analyzed because the assessment of HDAC2 and survivin proteins cannot be reliably performed with consistent results.

Arm/Group Title	Anaplastic Cancer
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	0

7. Secondary Outcome

Title	Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
Description	Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time Frame	Date treatment consent signed to date off study, approximately 12 months and 13 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Anaplastic Thyroid Cancer	Poorly Differentiated/Variants of Thyroid Cancer
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.	CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
Measure Participants	4	3
Count of Participants [Participants]	4 100%	3 100%

Adverse Events

Time Frame	Date treatment consent signed to date off study, approximately 12 months and 13 days.
Arm/Group Title	Anaplastic Thyroid Cancer		Poorly Differentiated/Variants of Thyroid Cancer
Arm/Group Description	CUDC-907 for anaplastic thyroid cancer CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.		CUDC-907 for Poorly differentiated and aggressive variants of differentiated thyroid cancer. CUDC-907: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day, 5 days on and 2 days off.
All Cause Mortality
	Anaplastic Thyroid Cancer		Poorly Differentiated/Variants of Thyroid Cancer
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/4 (50%)		1/3 (33.3%)
Serious Adverse Events
	Anaplastic Thyroid Cancer		Poorly Differentiated/Variants of Thyroid Cancer
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/4 (50%)		1/3 (33.3%)
General disorders
Death	2/4 (50%)	2	1/3 (33.3%)	1
Other (Not Including Serious) Adverse Events
	Anaplastic Thyroid Cancer		Poorly Differentiated/Variants of Thyroid Cancer
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	4/4 (100%)		3/3 (100%)
Blood and lymphatic system disorders
Anemia	0/4 (0%)	0	2/3 (66.7%)	4
Gastrointestinal disorders
Abdominal pain	1/4 (25%)	1	0/3 (0%)	0
Constipation	1/4 (25%)	1	0/3 (0%)	0
Diarrhea	1/4 (25%)	1	2/3 (66.7%)	3
Nausea	1/4 (25%)	2	0/3 (0%)	0
Pain	0/4 (0%)	0	1/3 (33.3%)	1
Vomiting	1/4 (25%)	3	0/3 (0%)	0
General disorders
Fatigue	4/4 (100%)	5	0/3 (0%)	0
Investigations
Alkaline phosphatase increased	1/4 (25%)	1	1/3 (33.3%)	1
Lymphocyte count decreased	0/4 (0%)	0	2/3 (66.7%)	2
Neutrophil count decreased	0/4 (0%)	0	1/3 (33.3%)	1
Weight loss	1/4 (25%)	1	1/3 (33.3%)	1
White blood cell decreased	0/4 (0%)	0	1/3 (33.3%)	1
Metabolism and nutrition disorders
Hypokalemia	0/4 (0%)	0	1/3 (33.3%)	1
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb	1/4 (25%)	2	0/3 (0%)	0
Non-cardiac chest pain	1/4 (25%)	1	0/3 (0%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain	1/4 (25%)	1	0/3 (0%)	0
Nervous system disorders
Dizziness	1/4 (25%)	1	0/3 (0%)	0
Renal and urinary disorders
Proteinuria	1/4 (25%)	1	0/3 (0%)	0
Respiratory, thoracic and mediastinal disorders
Dyspnea	0/4 (0%)	0	1/3 (33.3%)	2
Vascular disorders
Thromboembolic event	1/4 (25%)	1	0/3 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.